Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Aignostics logo — AI-powered precision diagnostics for pathology

Aignostics

AI-powered precision diagnostics for pathology

Founded 2018 Germany Berlin, Germany 114 employees Series B Total: $53.80M AI, Health Care +1

General Information

Company Name Aignostics
Founded Year 2018
Location Germany Berlin, Germany +1
Employees 114
Industries AI, Health Care, Machine Learning
Funding Stage Series B
Social

Get notified when Aignostics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Product Launch Sep 03, 2026

Aignostics launched LUCAID, a new multimodal, agentic AI system for lung cancer pathology, matching expert-panel consensus in 93% of decisions.

New Partnership Sep 02, 2026

Aignostics announced joint work on their LUCAID system with BIFOLD - Berlin Institute for the Foundations of Learning and Data and several other institutions.

Feature Release Aug 14, 2026

Aignostics launched ovarian cancer support for its Atlas H&E-TME product, expanding its coverage to nine cancer types.

Event Participation Aug 13, 2026

Aignostics will participate as an Exhibitor and Presenter at the ESP Congress, taking place on September 15, 2026, showcasing products and giving a presentation.

Get alerts when Aignostics shows new signals

AI Insight

Bounce Watch AI
2 months ago

Aignostics is demonstrating significant operational momentum, highlighted by the recent launch of Atlas 2, their advanced vision foundation model, which underscores continuous technological innovation in pathology AI. Concurrently, a strategic partnership with the Pancreatic Cancer Action Network signals a targeted expansion into specific disease areas and broader application of their AI platform. These developments showcase accelerated product maturity and strategic market penetration.

Signal Types
Product Launch Partnership Hiring Public Relations
Strategic Labels
Product Innovation Market Expansion AI Platform Enhancement
Next Move: Expansion
·
Impact: 8/10
·
Ideal For: Healthcare AI VCs — Series B

About Aignostics

Aignostics, established in 2018 as a spin-off from Charité Berlin, leverages AI and machine learning to drive advancements in precision diagnostics for pathology. Their innovative platform provides unparalleled insights across various therapeutic areas, making a significant impact on drug discovery, translational research, and clinical trials. With headquarters in Germany and operations in Berlin and New York, Aignostics represents a dynamic intersection of healthcare and technology.

The company recently secured a $34.00M Series B funding round on 01 October 2024, bolstered by industry heavyweights including IBB Ventures, Wellington Partners, HTGF, Mayo Clinic, CARMA FUND Management GmbH, Athos, and the Boehringer Ingelheim Venture Fund. This influx of capital underlines strong investor confidence in Aignostics' potential to spearhead the next generation of precision medicine solutions.

Taxonomy: AI-powered precision diagnostics, multimodal clinical datasets, precision medicine, digital pathology, explainable AI, immuno-oncology, neurodegenerative disease, companion diagnostics, computational pathology, predictive analytics, deep learning, target identification, biomarkers, translational research, drug discovery

Services & Products

Target & Biomarker Discovery
Translational Research
Digital Diagnostics
Custom Image and Data Analysis

Target Customers

Life Sciences Companies Academic Institutions Healthcare Providers Research Organizations

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 7
Investor Investor Investor Investor Investor
•••• •••• 		01 Oct 2024
Series A •••••• 4
Investor Investor Investor
•••• •••• 		01 Sep 2022
Seed •••••• 4
Investor Investor
•••• •••• 		01 Aug 2020
Seed •••••• - 01 Apr 2019
Support Program •••••• 1 •••• •••• 01 Jul 2018

View All 6 Funding Rounds

Latest News

View All
19 AI healthtechs to watch, according to VCs — Sifted
19 AI healthtechs to watch, according to VCs
Sifted Apr 05, 2024
Berlin-based Aignostics secures €31.4 million Series B to enhance precision medicine with AI — Eu-startups
Berlin-based Aignostics secures €31.4 million Series B to enhance precision medicine with AI
Eu-startups Nov 01, 2024

Aignostics Alternatives & Competitors

View All Alternatives
Aignostics vs
PredxBio
PredxBio United States

Reimagining Cancer Care with AI-Driven Spatial Biomarkers

Convertible Note
14 employees
AI, Biopharma
Compare Aignostics vs PredxBio
Aignostics vs
xMD Diagnostics, Inc.
xMD Diagnostics, Inc. United States

Enabling precision diagnostics

Non Equity Assistance
2 employees
Biotechnology, Health Care
Compare Aignostics vs xMD Diagnostics, Inc.
Aignostics vs
PATHWEST LABORATORY MEDICINE WA
PATHWEST LABORATORY MEDICINE WA Australia

Testing for today, teaching for tomorrow.

790 employees
Health Care
Compare Aignostics vs PATHWEST LABORATORY MEDICINE WA
View all alternatives

FAQ About Aignostics

AI-powered precision diagnostics for pathology
Aignostics was founded in 2018.
Aignostics is headquartered in Berlin, Germany.
Aignostics operates in the following industries: AI, Health Care, Machine Learning.
Aignostics has approximately 114 employees.
Aignostics has completed 6 funding rounds, raising a total of $53.80M. The latest funding stage is Series B.
Aignostics offers: Target & Biomarker Discovery, Translational Research, Digital Diagnostics, Custom Image and Data Analysis.
Top alternatives and competitors to Aignostics include PredxBio, xMD Diagnostics, Inc., PATHWEST LABORATORY MEDICINE WA, EmeritusDX - A Cancer Diagnostic and Information Company, Ibex Medical Analytics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Aignostics and PredxBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Aignostics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy